gabriel ventures corp

276 5th ave. ste. 704
new york, new york 10001

NYS Entity Status
ACTIVE

NYS Filing Date
AUGUST 21, 2013

NYS DOS ID#
4448919

County
NEW YORK

Jurisdiction
NEW YORK

Registered Agent
NONE

NYS Entity Type
DOMESTIC BUSINESS CORPORATION

Name History
2013 - GABRIEL VENTURES CORP









Buffer



submit to reddit

Telephone
n/a

Fax
n/a

Website
n/a

Email address
n/a

LinkedIn
n/a

Facebook
n/a

Google+
n/a

Twitter
n/a

Pinterest
n/a

Instagram
n/a



  • Around the Web

  • Billionaires, Bruised Egos, and the Death of a Grand Project
    By CHARLES V. BAGLI and ROBIN POGREBIN - Sunday Sep 24, 2017

    Barry Diller was about to win the battle for his $250 million arts pier, but then came the “petty questions” from his opponents and he decided to pull the plug.

    Source: NYT > Home Page
  • Near The East River, Plans Emerge For NY’s Next Life Science Center
    By Ben Fidler - Monday Aug 21, 2017

    At a time when biotech incubators and shared spaces are beginning to multiply in Manhattan, work on what could rank among the city’s largest biotech centers—if it can all come together—is just getting underway. According to Paul Wexler, a longtime healthcare-focused real estate broker, construction should begin next year on what is being called the […]

    Source: Xconomy New York
  • Alexandria Debuts NY’s Latest Bio Incubator With 13 Startups in Tow
    By Ben Fidler - Tuesday Jun 13, 2017

    A new startup incubator has just opened in Manhattan this morning, adding to a growing list of facilities meant to help support seedling New York City biotechs. LaunchLabs, first announced by Alexandria Real Estate Equities a year ago, officially opened its doors and revealed the 13 startups that will grow there. LaunchLabs is a 15,000-square-foot […]

    Source: Xconomy New York
  • What Steps Should NY Biotech Take in 2018? Share Your View on Dec. 11
    By Ben Fidler - Monday Nov 20, 2017

    Change takes time. Particularly in the life sciences, where a single drug’s journey from idea to market can consist of more than a decade of small, yet critical steps. For New York, then, aspirations to become a region known for its biotech industry are—and always have been—a long game in which every year and bit […]

    Source: Xconomy New York
  • Aquantia Announces Pricing of Initial Public Offering
    By Business Wire - Thursday Nov 2, 2017

    Aquantia Corp today announced the pricing of its initial public offering of 6,818,000 shares of its common stock at a price to the public of $9.00 per share. The shares are expected to begin trading on The New York Stock Exchange on...

    Source: VentureBeat